This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
ISEE2009 (Gather 2)
An Open-Label Extension (OLE) Phase 3 Trial To Assess The Safety Of Intravitreal Administration Of Avacincaptad Pegol (Complement C5 Inhibitor) In Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (Gather 2)
Overview
An open-label extension study for those patients who have completed participation in the Gather2 trial for Geographic atrophy. Participants will receive monthly intravitreal administrations of Avacincaptad Pegol (Complement C5 Inhibitor) for 18 months.
- Principal Investigator
Dr Thanh Nguyen
An open-label extension study for those patients who have completed participation in the Gather2 trial for Geographic atrophy. Participants will receive monthly intravitreal administrations of Avacincaptad Pegol (Complement C5 Inhibitor) for 18 months.
- Principal Investigator